NRSNW
Price:
$0.18
Market Cap:
$23.95M
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
NRSNW
According to NeuroSense Therapeutics Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.19. This represents a change of -81.45% compared to the average of -1.02 of the last 4 quarters.
The mean historical PE Ratio of NeuroSense Therapeutics Ltd. over the last ten years is -2.68. The current -0.19 PE Ratio has changed 609.52% with respect to the historical average. Over the past ten years (40 quarters), NRSNW's PE Ratio was at its highest in in the September 2023 quarter at 3.08. The PE Ratio was at its lowest in in the December 2021 quarter at -66.64.
Average
-2.68
Median
-1.91
Minimum
-6.39
Maximum
-1.06
Discovering the peaks and valleys of NeuroSense Therapeutics Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -1.06
Minimum Annual Increase = -56.63%
Minimum Annual PE Ratio = -6.39
Year | PE Ratio | Change |
---|---|---|
2023 | -1.06 | -15.48% |
2022 | -1.25 | -34.50% |
2021 | -1.91 | -30.96% |
2020 | -2.77 | -56.63% |
The current PE Ratio of NeuroSense Therapeutics Ltd. (NRSNW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.41
5-year avg
-2.68
10-year avg
-2.68
NeuroSense Therapeutics Ltd.’s PE Ratio is greater than NeuroSense Therapeutics Ltd. (-2.25), greater than Pasithea Therapeutics Corp. (-0.23), less than GeoVax Labs, Inc. (-0.17), greater than NLS Pharmaceutics AG (-90.25), greater than Cingulate Inc. (-1.18),
Company | PE Ratio | Market cap |
---|---|---|
-2.25 | $23.95M | |
-0.23 | $3.78M | |
-0.17 | $13.91M | |
-90.25 | $7.33M | |
-1.18 | $11.86M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuroSense Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeuroSense Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is NeuroSense Therapeutics Ltd.'s PE Ratio?
How is the PE Ratio calculated for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the highest PE Ratio for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the 3-year average PE Ratio for NeuroSense Therapeutics Ltd. (NRSNW)?
What is the 5-year average PE Ratio for NeuroSense Therapeutics Ltd. (NRSNW)?
How does the current PE Ratio for NeuroSense Therapeutics Ltd. (NRSNW) compare to its historical average?